Seek Returns

ALNY vs. ZTS: Alnylam Pharmaceuticals vs. Zoetis Stock Comparison

How do Alnylam Pharmaceuticals (ALNY) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Alnylam Pharmaceuticals (ALNY) and Zoetis (ZTS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while ZTS is classified in Pharmaceuticals.

Company profile comparison for Alnylam Pharmaceuticals (ALNY) and Zoetis (ZTS)
Profile ItemALNYZTS
NameAlnylam Pharmaceuticals, Inc.Zoetis Inc. Class A Common Stock
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization20.89 billion USD32.26 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateJune 1, 2004February 1, 2013
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ALNY
ZTS
GSPC
Loading price history…
Alnylam Pharmaceuticals (ALNY) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Alnylam Pharmaceuticals (ALNY) and Zoetis (ZTS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Alnylam Pharmaceuticals (ALNY) and Zoetis (ZTS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Alnylam Pharmaceuticals (ALNY) and Zoetis (ZTS)
MetricALNYZTS
Total Return (1Y)-64.57%-30.10%
Total Return (3Y, Annualized)-1.58%-20.42%
Total Return (5Y, Annualized)-3.13%-16.87%

Risk Profile

Drawdown History

ALNY
ZTS
GSPC
Loading price history…
Alnylam Pharmaceuticals (ALNY) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Alnylam Pharmaceuticals (ALNY) and Zoetis (ZTS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Alnylam Pharmaceuticals (ALNY) and Zoetis (ZTS)
MetricALNYZTS
Volatility (1Y, Annualized)54.08%38.23%
Beta (5Y)0.450.66
Max Drawdown (5Y)-68.25%-70.45%
Avg. Volume (3M)1.90M4.65M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ALNY and ZTS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Alnylam Pharmaceuticals (ALNY) and Zoetis (ZTS)
MetricALNYZTS
Sharpe Ratio (1Y)-1.27-0.90
Sortino Ratio (1Y)-1.45-1.10

Profitability

ROE (TTM)

Both companies show strong equity returns, but Alnylam Pharmaceuticals (ALNY) at 138.07% is the standout with ROE above its industry range; Zoetis (ZTS) at 57.63% also sits in the top quartile.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

138.07%

ALNY
138.07%
Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.63%

Max
109.18%
ZTS
57.63%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Zoetis (ZTS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Alnylam Pharmaceuticals (ALNY) at 52.85% and Zoetis (ZTS) at 26.41% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

52.85%

ALNY
52.85%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.41%

ZTS
26.41%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Zoetis (ZTS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Alnylam Pharmaceuticals (ALNY) at 23.72% and Zoetis (ZTS) at 38.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.72%

Max
83.12%
ALNY
23.72%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.19%

Max
83.12%
ZTS
38.19%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Zoetis (ZTS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Alnylam Pharmaceuticals (ALNY) and Zoetis (ZTS)
MetricALNYZTS
ROE (TTM)138.07%57.63%
ROA (TTM)9.51%14.87%
Net Margin (TTM)52.85%26.41%
Operating Margin (TTM)23.72%38.19%
Gross Margin (TTM)77.28%71.65%

Growth

Revenue Growth

Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Zoetis (ZTS) at 2.28% is closer to the peer norm — faster top-line expansion for ALNY.

Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Zoetis (ZTS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Zoetis (ZTS) reports EPS growth of 10.05%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.

Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Zoetis (ZTS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Alnylam Pharmaceuticals (ALNY) and Zoetis (ZTS)
MetricALNYZTS
Revenue Growth (YoY)65.19%2.28%
Revenue Growth (3Y CAGR)52.98%5.42%
EPS Growth (YoY)--10.05%
EPS Growth (3Y CAGR)--10.27%

Financial Strength

Current Ratio (MRQ)

Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while Zoetis (ZTS) at 2.35 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ZTS.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.48

Max
25.13
Q3
12.13
Median
5.52
ALNY
2.48
Q1
2.47
Min
0.10

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.35

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ZTS
2.35
Min
0.10
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Zoetis (ZTS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both balance sheets lean debt-heavy versus peers, but ZTS is more stretched: Alnylam Pharmaceuticals (ALNY) at 0.83 sits in the higher-leverage quartile and Zoetis (ZTS) at 2.80 is above its industry benchmark range.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max
1.42
ALNY
0.83
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.80

ZTS
2.80
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Zoetis (ZTS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Alnylam Pharmaceuticals (ALNY) and Zoetis (ZTS)
MetricALNYZTS
Current Ratio (MRQ)2.482.35
Debt / Equity (MRQ)0.832.80
Net Debt / EBITDA-0.571.92

Dividends

Dividend Yield (TTM)

Alnylam Pharmaceuticals (ALNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a yield of 2.55%, ranking against industry peers normally.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ALNY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.55%

ZTS
2.55%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Zoetis (ZTS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Alnylam Pharmaceuticals (ALNY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a payout of 35.24%, ranking against industry peers normally.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ALNY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.24%

ZTS
35.24%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Zoetis (ZTS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Alnylam Pharmaceuticals (ALNY) and Zoetis (ZTS)
MetricALNYZTS
Dividend Yield (TTM)0.00%2.55%
Dividend Payout Ratio (TTM)0.00%35.24%

Valuation

P/E Ratio (TTM)

Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Zoetis (ZTS) at 13.50 is closer to its industry’s usual earnings multiple — a discount for ALNY, though growth and earnings durability still matter.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.88

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
ALNY
7.88
Min
0.07

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.50

Max
85.34
Q3
43.46
Median
26.69
ZTS
13.50
Q1
13.30
Min
0.07
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Zoetis (ZTS): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Zoetis (ZTS) at 3.40 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.17

Max
58.18
Q3
25.77
Median
7.30
ALNY
4.17
Q1
3.01
Min
0.01

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.40

Max
58.18
Q3
25.77
Median
7.30
ZTS
3.40
Q1
3.01
Min
0.01
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Zoetis (ZTS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Alnylam Pharmaceuticals (ALNY) at 5.79 is valued about in line with its industry on P/B ratio, while Zoetis (ZTS) at 9.80 carries an above-peer premium to book — ZTS is pricier on assets.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.79

Max
13.53
Q3
6.54
ALNY
5.79
Median
3.25
Q1
1.69
Min
-5.59

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80

Max
13.53
ZTS
9.80
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Zoetis (ZTS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Alnylam Pharmaceuticals (ALNY) and Zoetis (ZTS)
MetricALNYZTS
P/E Ratio (TTM)7.8813.50
P/S Ratio (TTM)4.173.40
P/B Ratio (MRQ)5.799.80
Free Cash Flow Yield (TTM)1.57%6.36%